xCures Joins Big Names in Aetion’s New Initiative

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.

Aetion’s initiative will focus on better understanding the regulatory questions that can be answered using RWE and randomized controlled trials (RCTs), and when and why RWE and RCTs might yield the same or different results. It will conduct multiple trial emulations in various data sources, beginning with a one-year focus on oncology. Using the Aetion Evidence Platform, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.

“xCures has implemented real-time access to retrospective and prospective medical data, including the knowledge captured in unstructured notes and images, through a regulatory grade platform,” said Mika Newton, CEO of xCures. “This transforms the nature and scope of our understanding of patient outcomes and is critical to rapidly advancing research and care.” 

Other partners joining xCures in building this relationship with Aetion include AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women’s Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX,

For additional information, visit https://aetion.com/resources/care-initiative/

About Aetion

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from any institution a cancer patient visited and organizes them into a powerful care summary. This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The platform prospectively generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com.